**Acknowledgments**

This work was presented on the international conference "Vaccines & Vaccination", Moscow, September 27-October 1, 2017 http://www.onlinereg.ru/VAC&VAC2017 sponsored by Russian Science Fund 15\_15\_30039, and received the award for the best oral presentation. Authors acknowledge Scientific Committee and Conference organizers for support of the publication.

[6] Haynes BF, Burton DR. Developing an HIV vaccine. Science. 2017;**6330**:1129-1130. DOI:

Artificial Epitope-Based Immunogens in HIV-Vaccine Design

http://dx.doi.org/10.5772/intechopen.77031

219

[7] Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune correlates of vaccine protection against HIV-1 acquisition. Science Translational Medicine.

[8] Billich A. AIDSVAX (VaxGen). Current Opinion in Investigational Drugs. 2004;**2**:214-221

[9] O'Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harbor Perspectives in Medicine. 2012;**12**:a007351. DOI: 10.1101/csh-

[10] Haynes BF. New approaches to HIV vaccine development. Current Opinion in Immu-

[11] Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, De Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine. 2009;**23**:2209-2220.

[12] Hsu DC, O'Connell RJ. Progress in HIV vaccine development. Human Vaccines and Immunotherapeutics. 2017;**5**:1018-1030. DOI: 10.1080/21645515.2016.1276138

[13] Karpenko LI, Bazhan SI, Antonets DV, Belyakov IM. Novel approaches in polyepitope T-cell vaccine development against HIV-1. Expert Review of Vaccines. 2014;**1**:155-173.

[14] Eroshkin AM, Zhilkin PA, Shamin VV, Korolev S, Fedorov BB. Artificial protein vaccines with predetermined tertiary structure: Application to anti-HTV-1 vaccine design. Protein Engineering, Design and Selection. 1993;**8**:997-1001. DOI: 10.1093/protein/

[15] Eroshkin AM, Karginova EA, Gileva IP, Lomakin AS, Lebedev LR, Kamyinina TP, Pereboev AV, Ignat'ev GM. Design of four-helix bundle protein as a candidate for HIV vaccine. Protein Engineering, Design and Selection. 1995;**2**:167-173. DOI: 10.1093/

[16] Mikhailov AM, Loktev VB, Lebedev LR, Eroshkin AM, Kornev AN, Kornilov VV, Vainshtein BK. Crystallization and X-ray study of the artificial TBI protein, an experimental multiple-epitope vaccine against type 1 human immunodeficiency virus. Crystallography

[17] Loktev VB, Ilyichev AA, Eroshkin AM, Karpenko LI, Pokrovsky AG, Pereboev AV, Svyatchenko VA, Ignat'ev GM, Smolina MI, Melamed NV, Lebedeva CD, Sandakhchiev LS. Design of immunogens as components of a new generation of molecular vaccines.

Journal of Biotechnology. 1996;**1-3**:129-137. DOI: 10.1016/0168-1656(95)00089-5

2015;**310**:310rv7-310rv7. DOI: 10.1126/scitranslmed.aac7732

nology. 2015;**35**:39-47. DOI: 10.1016/j.coi.2015.05.007

10.1126/science.aan0662

perspect.a007351

DOI: 10.1056/NEJMoa0908492

DOI: 10.1586/14760584.2014.861748

6.8.997

protein/8.2.167

Reports. 1999;**5**:868-870
